Heidelberg

• A clinical study of ifinatamab deruxtecan and pembrolizumab with or without chemotherapy in people with esophageal cancer (MK-3475-06E) Recruiting
  2024-514273-22-00 9 2025-09-02 Esophageal squamous cell carcinoma
• Study of Daraxonrasib (RMC-6236) in Patients with RAS Mutated NSCLC Recruiting
  2024-518154-16-00 5 2025-08-27 non-small cell lung cancer
• EORTC 2022-MG: Treatment with tebentafusp or observation for patients with melanoma of the eye after surgery or radiation (ATOM Trial) Recruiting
  2023-510333-28-00 5 2025-08-20 Uveal Melanoma
• A clinical study of ifinatamab deruxtecan to treat metastatic prostate cancer (MK 2400 01A) Recruiting
  2024-516036-94-00 9 2025-08-12 Metastatic castrate resistant prostate cancer - mCRPC
• A clinical study of V940 and pembrolizumab in people with melanoma (V940-012) Recruiting
  2024-519605-36-00 4 2025-08-08 Melanoma
• Safety and Efficacy of Intravenous Thrombolysis in Patients with Ischemic Stroke on Treatment with Direct Oral Anticoagulants: DO-IT – The D … Recruiting
  2024-515561-34-01 6 2025-08-04 Acute ischemic stroke with recent ingestion of direct oral anticoagula
• A Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituxima … Recruiting
  2024-518893-15-00 5 2025-07-29 Chronic lymphotic leukemia and Small Lymphocytic lymphoma
• A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Recruiting
  2024-520154-38-00 5 2025-07-29 Acute Myeloid Luekemia
• A Study of ASTX030 (Cedazuridine in Combination with Azacitidine) in MDS, CMML, or AML Recruiting
  2024-515098-93-00 5 2025-07-22 Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML
• Recombinant coagulation Factor VIIa administered at the earliest time for the treatment of stroke caused by bleeding in the brain - FASTEST … Recruiting
  2024-517383-28-00 5 2025-07-21 Acute haemorrhagic stroke
• Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab – A randomized, placebo-controlled, double-blin … Recruiting
  2023-506887-15-00 4 2025-07-14 Hepatocellular carcinoma
• A Study to Assess safety and Effectiveness of the Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor an … Recruiting
  2024-516162-11-00 5 2025-07-14 Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3CA)-Mutated, Ho
• Evaluation of efficacy and safety of Cemiplimab as first line treatment for advanced basal cell carcinoma (CEMI-first) - An open label, sing … Recruiting
  2024-517647-31-00 4 2025-07-09 basal cell carcinoma
• A Study to Evaluate Tobevibart+Elebsiran in Participants with Chronic HDV Infection Not Virologically Suppressed with Bulevirtide Recruiting
  2024-519282-22-00 5 2025-07-09 Chronic Hepatitis D Virus (HDV) Infection
• Master protocol of TCR-modified T cell therapy targeting HLA-restricted KRAS antigen administered in adult patients with metastatic or local … Recruiting
  2024-513900-32-00 7 2025-07-03 Pancreatic Ductal Adenocarcinoma
• A Trial of a novel agent in participants with previously treated Immunoglobulin Light-Chain (AL) Amyloidosis Recruiting
  2024-519191-90-00 4 2025-07-02 Immunoglobulin Light-Chain (AL) Amyloidosis
• Safety and clinical parameter assessment of self-infusion therapy with Prolastin® in patients with severe AATD Recruiting
  2024-515894-80-00 5 2025-07-01 Severe Alpha-1 Antitrypsin Deficiency (AATD)
• "A research study comparing different doses of CDR132L with placebo on the structure and function of the heart in people with heart failure … Recruiting
  2024-515796-35-00 4 2025-06-26 Heart Failure with Preserved Ejection Fraction and Left Ventricular Hy
• A research study comparing CDR132L with placebo on the structure and function of the heart in people with heart failure with reduced/mildly … Recruiting
  2024-515797-27-00 4 2025-06-25 Heart Failure with Reduced/Mildly Reducede Ejection Fraction and Left
• A Phase III study to evaluate the efficacy of INM004 (Shiga antitoxin) in pediatric patients with Shiga toxin-producing Escherichia coli-ass … Recruiting
  2024-512412-22-00 5 2025-06-24 Hemolytic Uremic Syndrome
• Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction Recruiting
  2024-519219-32-00 5 2025-06-23 Heart Failure With Reduced Ejection Fraction
• Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting
  2024-515764-31-00 10 2025-06-13 Non-small cell lung cancer
• A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration ( … Recruiting
  2023-510294-34-00 5 2025-06-12 small lymphocytic lymphoma (SLL)
• BIOmarker driven intensification of cardiovascular RISK factor management in patients with high risk for recurrent cardiovascular EVENTs The … Recruiting
  2024-511950-35-00 5 2025-06-12 Acute Myocardial Infarction

Showing 193–216 of 732 trials